ViiV Healthcare in public tender agreement with Botswana for HIV treatment dolutegravir

3 June 2016

Global HIV specialist firm ViiV Healthcare has confirmed a public tender agreement with the Ministry of Health in Botswana to support the implementation of a new national ‘Treat All’ program aiming to ensure people living with the virus in the country receive treatment with Tivicay (dolutegravir).

For the first time, dolutegravir will be made available as part of a national health program in sub-Saharan Africa since the World Health Organization (WHO) recommended it as alternative first line treatment in HIV patients in late 2015.

For ViiV Healthcare, which is majority-owned by UK major GlaxoSmithKline (LSE: GSK), with US pharma giant Pfizer (NYSE: PFE) and Japan’s Shionogi (TYO: 4507) as shareholders, it is the largest tender it has ever secured in the African sub-continent. The region is particularly impacted by the virus, with nearly three quarters of the global HIV population living there.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK